Life Sciences company focusing on research and development of psychedelic pharmaceuticals PharmaTher Holding Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having submitted an application to commence its phase 2 clinical trials to assess the safety, pharmacokinetics and efficacy of using a low dose of ketamine during treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (LID-PD).
PharmaTher submitted the investigational new drug application with the United Stated Food and Drug Administration (FDA) on April 20 to initiate the phase 2 clinical trials.
FDA has approved ketamine as N-methyl-D-aspartate (“NMDA”) receptor-modulating drug that is largely used as an anesthetic agent on its own or in combination with other anesthetic drugs.
“The submission of our IND application with the FDA is an important milestone as it provides us with a solid foundation to advance our ambition in commercializing ketamine and unlocking its therapeutic potential through novel uses, formulations and delivery methods in the treatment of neurodegenerative diseases, mental illness and chronic pain,” said the company’s CEO, Fabio Chianelli.
